Amarin Corp Ads (AMRN) 2.91 $AMRN
Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
Marketwired - Thu Jul 28, 6:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - July 28, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2016 financial results and provide an operational update on Thursday, August 4, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.91 (+0.26)
Coverage Initiated on Select Drug Manufacturers' Stocks
ACCESSWIRE - Fri Jul 15, 8:16AM CDT
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
UTHR: 125.08 (+4.07), AMRN: 2.91 (+0.26), DEPO: 19.32 (+0.35), IONS: 38.01 (+8.82)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 125.08 (+4.07), AMRN: 2.91 (+0.26), DEPO: 19.32 (+0.35), IONS: 38.01 (+8.82)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Marketwired - Sat Jun 11, 10:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins that could promote fat deposits in arteries) in patients with Type 2 diabetes and persistent high triglyceride (TG) levels despite statin therapy.
AMRN: 2.91 (+0.26)
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Marketwire Canada - Mon Jun 06, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - June 06, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.
AMRN: 2.91 (+0.26)
Amarin (AMRN) Looks Good: Stock Adds 6.7% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:40AM CDT
Amarin Corporation plc (AMRN) saw its shares rise almost 7% in the last trading session.
ANIP: 61.06 (+0.46), AMRN: 2.91 (+0.26)
Amarin to Present at the Jefferies 2016 Global Healthcare Conference
Marketwire Canada - Wed Jun 01, 7:01AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 01, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2016 Global Healthcare Conference in New York City on Tuesday, June 7, 2016, at 8:00 a.m. ET.
AMRN: 2.91 (+0.26)
Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
Marketwire Canada - Tue May 31, 12:30PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval.
AMRN: 2.91 (+0.26)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
Marketwired - Fri May 20, 9:50AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 20, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels.
AMRN: 2.91 (+0.26)
Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
Marketwire Canada - Wed May 11, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - May 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) and eicosapentaenoic acid (EPA) will be presented at the upcoming National Lipid Association 2016 Scientific Sessions in New Orleans (May 19-22).
AMRN: 2.91 (+0.26)
Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
Marketwire Canada - Thu May 05, 6:00AM CDT
Product Revenue up 63% Over Prior Year; REDUCE-IT Cardiovascular Outcomes Study Achieves Target Enrollment; Preparation for Interim Analysis by Independent Data Monitoring Committee Underway; Management to Host Conference Call at 8:00 a.m. ET Today
AMRN: 2.91 (+0.26)
Investor Calendar Invites You to the Amarin First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 5, 2016
ACCESSWIRE - Wed May 04, 3:05PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / May 4, 2016 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 5, 2016 at 8:00 AM Eastern Time.
AMRN: 2.91 (+0.26)
Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
Marketwired - Thu Apr 28, 6:44AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2016 financial results and provide an operational update on Thursday, May 5, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.91 (+0.26)
Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
Marketwired - Thu Jul 28, 6:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - July 28, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2016 financial results and provide an operational update on Thursday, August 4, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.91 (+0.26)
Coverage Initiated on Select Drug Manufacturers' Stocks
ACCESSWIRE - Fri Jul 15, 8:16AM CDT
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
UTHR: 125.08 (+4.07), AMRN: 2.91 (+0.26), DEPO: 19.32 (+0.35), IONS: 38.01 (+8.82)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 125.08 (+4.07), AMRN: 2.91 (+0.26), DEPO: 19.32 (+0.35), IONS: 38.01 (+8.82)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Marketwired - Sat Jun 11, 10:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins that could promote fat deposits in arteries) in patients with Type 2 diabetes and persistent high triglyceride (TG) levels despite statin therapy.
AMRN: 2.91 (+0.26)
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Marketwire Canada - Mon Jun 06, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - June 06, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.
AMRN: 2.91 (+0.26)
Amarin (AMRN) Looks Good: Stock Adds 6.7% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:40AM CDT
Amarin Corporation plc (AMRN) saw its shares rise almost 7% in the last trading session.
ANIP: 61.06 (+0.46), AMRN: 2.91 (+0.26)
Amarin to Present at the Jefferies 2016 Global Healthcare Conference
Marketwire Canada - Wed Jun 01, 7:01AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 01, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2016 Global Healthcare Conference in New York City on Tuesday, June 7, 2016, at 8:00 a.m. ET.
AMRN: 2.91 (+0.26)
Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
Marketwire Canada - Tue May 31, 12:30PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval.
AMRN: 2.91 (+0.26)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
Marketwired - Fri May 20, 9:50AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 20, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels.
AMRN: 2.91 (+0.26)
Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
Marketwire Canada - Wed May 11, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - May 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) and eicosapentaenoic acid (EPA) will be presented at the upcoming National Lipid Association 2016 Scientific Sessions in New Orleans (May 19-22).
AMRN: 2.91 (+0.26)
Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
Marketwire Canada - Thu May 05, 6:00AM CDT
Product Revenue up 63% Over Prior Year; REDUCE-IT Cardiovascular Outcomes Study Achieves Target Enrollment; Preparation for Interim Analysis by Independent Data Monitoring Committee Underway; Management to Host Conference Call at 8:00 a.m. ET Today
AMRN: 2.91 (+0.26)
Investor Calendar Invites You to the Amarin First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 5, 2016
ACCESSWIRE - Wed May 04, 3:05PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / May 4, 2016 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 5, 2016 at 8:00 AM Eastern Time.
AMRN: 2.91 (+0.26)
Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
Marketwired - Thu Apr 28, 6:44AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2016 financial results and provide an operational update on Thursday, May 5, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.91 (+0.26)
